Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
COMPAZINE (prochlorperazine) is a first-generation antipsychotic and antiemetic small molecule approved in 1957 for injection. It is primarily used to manage nausea, vomiting, and psychiatric symptoms across multiple indications. The drug works as a dopamine antagonist with antiemetic properties in the chemoreceptor trigger zone.
As an aging injectable with LOE approaching, the COMPAZINE team is likely focused on defending market share against generics rather than growth initiatives, signaling smaller commercial teams and cost-containment priorities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on COMPAZINE offers limited career growth opportunities given the mature lifecycle and approaching LOE; roles focus primarily on defending existing market share, managing generic competition, and optimizing costs rather than innovation or expansion. This product is best suited for professionals seeking stable, operational-focused positions in a legacy franchise rather than high-visibility growth assignments.
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.